Carmela Passaro

Biochemistry, Genetics and Molecular Biology · Life Sciences

18h-index1.7kcitations57works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(37), CAR-T cell therapy research(19), Viral Infectious Diseases and Gene Expression in Insects(15), Herpesvirus Infections and Treatments(13), Cancer Research and Treatments(10)

Publications57 total

Abstract B001: Effective generation of potent tumor-infiltrating lymphocytes (TIL) expressing regulatable membrane-bound IL15 (mbIL15) and LIGHT (TNFSF14) from immune-excluded chondrosarcoma
Cancer Immunology Research·2025
457 Engineered tumor-infiltrating lymphocytes (TIL) with co-regulated membrane-bound IL15 (mbIL15) and LIGHT (TNFSF14) generate significant antitumor efficacy in fibrotic tumor models
Regular and Young Investigator Award Abstracts·2024Open Access
Abstract LB065: Tumor-infiltrating lymphocytes (TIL) engineered with regulatable membrane-bound IL15 (mbIL15) and LIGHT (TNFSF14) show enhanced efficacy in fibroblast-containing cold tumors
Cancer Research·2024· 2 cited
Abstract LB093: Engineering tumor infiltrating lymphocytes from sarcoma and colorectal tumors with membrane bound IL-15 for IL-2 independent expansion and enhanced cytotoxicity against autologous tumor cell lines
Cancer Research·2023
Supplementary Data from Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy
2023Open Access
Supplementary Figures and Tables from Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma
2023Open Access
Supplementary Data from Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy
2023Open Access
Data from Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy
2023Open Access
Supplementary Figure 1 from Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy
2023Open Access
Supplementary Figure 3 from Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy
2023Open Access
Data from Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma
2023Open Access
Supplementary Figure 2 from Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy
2023Open Access
Supplementary Figure 1 from Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy
2023Open Access
Supplementary Figure 3 from Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy
2023Open Access
Data from Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma
2023Open Access
Supplementary Figures and Tables from Toxicity and Efficacy of a Novel GADD34-expressing Oncolytic HSV-1 for the Treatment of Experimental Glioblastoma
2023Open Access
Data from Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy
2023Open Access
Supplementary Figure 2 from Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy
2023Open Access
369 Enhancers of innate and adaptive immunity combine with membrane bound IL15 to increase the efficacy of tumor infiltrating lymphocyte (TIL) therapy for tumors with immunosuppressive microenvironments
Regular and Young Investigator Award Abstracts·2022· 1 citedOpen Access
<i>In Vivo</i> Delivery of a CD20 CAR Using a CD8-Targeted Fusosome in Southern Pig-Tail Macaques (<i>M. nemestrina</i>) Results in B Cell Depletion
Blood·2021· 4 cited
page 1 of 3Next →

Frequent Co-authors

Hiroshi Nakashima(23), Sean Lawler(20), Hirotaka Ito(18), David A. Reardon(18), Quazim A. Alayo(16), Maria C. Speranza(14), Gordon J. Freeman(14), E. Antonio Chiocca(14), Korneel Grauwet(14), William F. Goins(14), Giuseppe Portella(14), Vivek Bhaskaran(11), Marco Mineo(11), Khalid Shah(11), Soledad Fernández(11), Isabel DeLaura(10), Eric McLaughlin(10), John A. McNulty(9), E. Antonio Chiocca(8), Franz Ricklefs(6)